drugset
Drugs / 111In-CP04
last change Nov 2018 re-read 2 minutes ago

111In-CP04

also known as 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 · CP04

Peptide

Developed for
medullary thyroid gland carcinoma
Investigated by
Erasmus Medical Center · INRASTES, NCSR Demokritos, Athens, Greece · Jagiellonian University · Medical University Innsbruck · NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland · Paola Anna Erba
+2 more · University Hospital Freiburg · University Medical Centre Ljubljana

Trials 1 · a red edge is where a trial was stopped

today NCT03246659 · Ph 1
2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03246659 Aug 2016 → Nov 2018 medullary thyroid gland carcinoma Paola Anna Erba Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 111In-CP04 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03246659 ↗
Known as 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 “111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2” NCT03246659 ↗
Known as CP04 “radiolabelled peptide CP04” NCT03246659 ↗
Modality Peptide “radiolabelled peptide CP04” NCT03246659 ↗
Route Intravenous “i.v. administration” NCT03246659 ↗